← Xeris Biopharma Holdings, Inc. (XERS) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫
Xeris Biopharma Holdings, Inc. (XERS)
Pharmaceutical Preparations · market cap $1.6B · as of 2026-07-19
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2026-11-05 (est.)
Earnings
Pipeline
12
programs
Upcoming events
1
next 90d+
Dossier
Ready
cached
Xeris Biopharma Holdings (XERS) is a specialty pharma company with 394 employees and a ~$1.5B market cap, focused primarily on glucagon-based rescue and infusion therapies for hypoglycemia and diabetes. Its lead commercial asset is G-Pen (ready-to-use glucagon injection), with a broad pipeline spanning Phase 2 and Phase 3 programs across hypoglycemia, Type 1 diabetes, and hypothyroidism. Revenue has grown rapidly from $50M in 2021 to $292M in 2025, and the company reached near-breakeven net income of $1M in 2025.
The catalyst path
- 2026-11-05 (est.)Earningsimp 5/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| PRAM9 | Phase 2 | Diabetes Mellitus, Type 1 |
| G-Pen | Phase 3 | Insulin Hypoglycemia |
| Novo Nordisk GlucaGen® | Phase 2 | Hypoglycemia |
| levothyroxine sodium | Phase 2 | Hypothyroidism |
| G-Pump™ (glucagon infusion) | Phase 2 | Hypoglycemia |
| Glucagon | Phase 3 | Diabetes Mellitus, Type 1 |
| Glucagon RTU | Phase 2 | Hyperinsulinemic Hypoglycemia |
| Lilly Glucagon | Phase 3 | Insulin Hypoglycemia |
| Glucagon RTU Injection With Insulin Pump Reduction | Phase 2 | Hypoglycemia |
| G-Pen (glucagon injection) | Phase 3 | Hypoglycemia |
| G-Pen Mini™ (glucagon injection) | Phase 2 | Hypoglycemia |
| G-Pen(TM) 1 mg | Phase 2 | Hypoglycemia |
Price & technical context
3-month
+11.7%
6-month
+53.1%
12-month
+13.6%
52-wk range
$5.29–$9.98
vs 50-day MA
+9.5%
vs 200-day MA
+28.7%
Realized vol
54.2%
Max drawdown
-46.6%
Daily closes through 2026-10-01. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for XERS (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 12 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.